학술논문
The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe
Document Type
article
Author
Richard Nicholas; Jeff Rodgers; James Witts; Annalaura Lerede; Tim Friede; Jan Hillert; Lars Forsberg; Anna Glaser; Ali Manouchehrinia; Ryan Ramanujam; Tim Spelman; Pernilla Klyve; Jiri Drahota; Dana Horakova; Hanna Joensen; Luigi Pontieri; Melinda Magyari; David Ellenberger; Alexander Stahmann; Helmut Butzkueven; Anneke Van Der Walt; Vladimir Bezlyak; Carol Lines; Rod Middleton
Source
Therapeutic Advances in Neurological Disorders, Vol 16 (2023)
Subject
Language
English
ISSN
1756-2864
17562864
17562864
Abstract
Introduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT prescription guidelines and monitoring vary across countries. Standardising the approach to diagnosis of disease course, for example, assigning RRMS or secondary progressive MS (SPMS) diagnoses, allows examination of the impact of health system characteristics on the stated clinical diagnosis and treatment access. Methods: We analysed registry data from six cohorts in five countries (Czech Republic, Denmark, Germany, Sweden and United Kingdom) on patients with an initial diagnosis of RRMS. We standardised our approach utilising a pre-existing algorithm (DecisionTree, DT) to determine patient diagnoses of RRMS or secondary progressive MS (SPMS). We identified five global drivers of DMT prescribing: Provision, Availability, Funding, Monitoring and Audit, data were analysed against these concepts using meta-analysis and univariate meta-regression. Results: In 64,235 patients, we found variations in DMT use between countries, with higher usage in RRMS and lower usage in SPMS, with correspondingly lower usage in the UK compared to other registers. Factors such as female gender ( p = 0.041), increasing disability via Expanded Disability Status Scale (EDSS) score ( p = 0.004), and the presence of monitoring ( p = 0.029) in SPMS influenced the likelihood of receiving DMTs. Standardising the diagnosis revealed differences in reclassification rates from clinical RRMS to DT-SPMS, with Sweden having the lowest rate Sweden (Sweden 0.009, range: Denmark 0.103 – UK portal 0.311). Those with higher EDSS at index ( p